The Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Global Market Report 2023, provides comprehensive information on the methicillin-resistant staphylococcus aureus (mrsa) drugs market across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa for the 27 major global industries. The report covers a ten year historic period – 2010-2021, and a ten year forecast period – 2023-2032.
Learn More On The Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market’s Growth:
The global methicillin-resistant staphylococcus aureus drugs market size is expected to grow from $2.15 billion in 2022 to $2.26 billion in 2023 at a compound annual growth rate (CAGR) of 5.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global methicillin-resistant staphylococcus aureus drugs market size is expected to reach $2.73 billion in 2027 at a CAGR of 4.8%.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample_request?id=10859&type=smp
Product innovation is the key trend gaining popularity in the Methicillin-Resistant Staphylococcus aureus (MRSA) drug market. Major companies involved in the Methicillin-Resistant Staphylococcus Aureus (MRSA) drug market are focused on innovating new products to improve their observation power and sustain their position in the market. For instance, in March 2021, Melinta Therapeutics LLC, a US-based biopharmaceutical firm, announced the FDA approval of Kimyrsa (oritavancin), indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA). Kimyra is the first oritavancin one-hour infusion product prepared from one 1,200 mg vial and is compatible with both 0.9% sodium chloride injection (NS) and 5% dextrose in sterile water (D5W). The drug acts by inhibiting transpeptidation, inhibiting transglycosylation, and disrupting cell membrane integrity.
The methicillin-resistant staphylococcus aureus (mrsa) drugs market is segmented:
1) By Drug Class: Lipopeptides, Oxazolidinones, Cephalosporin, Tetracycline, Folate Antagonist, Lipoglycopeptide, Other Drug Classes
2) By Indication: Skin Infections, Bone and Joint Infections, Bacteremia, Animal Infections
3) By MRSA Type: Hospital-Acquired (HA-MRSA), Community-Acquired (CA-MRSA)
4) By Route of Administration: Oral Administration, Parenteral Administration
5) By End User: Hospitals and Clinics, Research and Academic Institutes, Other End-Users
North America was the largest region in the methicillin-resistant staphylococcus aureus (mrsa) drugs market in 2022.
The table of contents in TBRC’s methicillin-resistant staphylococcus aureus (mrsa) drugs market report includes:
- Executive Summary
- Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Characteristics
- Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Trends And Strategies
- Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market – Macro Economic Scenario
- Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Size And Growth
.
.
.
- Africa Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market
- Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Competitive Landscape And Company Profiles
- Key Mergers And Acquisitions In The Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market
- Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Future Outlook and Potential Analysis
- Appendix
Learn About Us:
The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries. Through the report businesses can gain a thorough understanding of the market’s size, growth rate, major drivers and leading players.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
